US Stock MarketDetailed Quotes

RNXT RenovoRx

Watchlist
  • 1.040
  • +0.010+0.97%
Close Feb 14 16:00 ET
  • 1.060
  • +0.020+1.92%
Post 20:01 ET
36.99MMarket Cap-1.79P/E (TTM)

About RenovoRx Company

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. Its therapy platform includes RenovoTAMP, a therapy platform designed for targeted delivery of chemotherapy enabling localized treatment of solid tumors. The company was founded by Ramtin Agah and Kamran Najmabadi in December 2009 and is headquartered in Mountain View, CA.

Company Profile

SymbolRNXT
Company NameRenovoRx
Listing DateAug 26, 2021
Issue Price9.00
Founded2012
CEOMr. Shaun R. Bagai
MarketNASDAQ
Employees8
Fiscal Year Ends12-31
Address2570 West El Camino Real,Suite 320
CityMountain View
ProvinceCalifornia
CountryUnited States of America
Zip Code94040
Phone1-650-284-4433
Websitehttp://www.renovorx.com

Company Executives

  • Name
  • Position
  • Salary
  • Shaun R. Bagai
  • Chief Executive Officer and Director
  • 939.12K
  • Leesa Gentry
  • Chief Clinical Officer
  • --
  • Dr. Ramtin Agah, M.D.
  • Chief Medical Officer and Chairman of the Board
  • 507.76K
  • Ronald B. Kocak
  • Vice President, Controller and Principal Accounting Officer
  • --
  • Dr. Una S. Ryan,PhD
  • Independent Director
  • 82.00K
  • Kirsten Angela Macfarlane
  • Independent Director
  • 82.00K
  • Dr. Robert J. Spiegel, F.A.C.P.,M.D.
  • Independent Director
  • 173.72K
  • Dr. Laurence J. Marton, M.D.
  • Independent Director
  • 77.00K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
PILOT
831175
+30.00%
XINGANJIANG
873167
+29.99%
Beijing Highlander Digital Technology
300065
+20.05%
4
Hangzhou Gaoxin Materials Technology
300478
+20.02%
5
Shijihengtong Technology
301428
+20.01%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Monetary Policy: Navigating the Fed's Rate Cut Cycle
Changing Fed policy is altering the market math for investors.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More
TSLA earnings preview: Grab rewards by guessing the opening price!